跳至主要内容
临床试验/NCT00309660
NCT00309660Unknown1 期

Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

Herlev Hospital2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2005年11月最近更新:
适应症
相关药物

试验速览

阶段
1 期
入组人数
20
试验地点
2
主要终点
Clinical response

研究概览

简要总结

Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Distal ulcerative colitis (Mayo Clinical Score > 7)
  • Age > 18 years
  • Written consent

排除标准

  • Age < 18 years
  • Severe ulcerative colitis
  • Systemic treatment with steroids or azathioprin within the last 3 month
  • Known liver or kidney disease
  • Severe heart failure
  • Pregnancy or breast feeding

结局指标

主要结局

Clinical response

次要结局

  • Endoscopic response

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Treatment With Local PPARgamma Ligand in Distal... | 临床试验